Journal article
B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease
RAH Stewart, A Kirby, HD White, SL Marschner, M West, PL Thompson, D Sullivan, E Janus, D Hunt, L Kritharides, A Keech, J Simes, AM Tonkin
Journal of the American Heart Association | Published : 2022
Abstract
BACKGROUND: The plasma concentration of B-type natriuretic peptide (BNP) is a strong predictor of adverse cardiovascular events. The aim of this study was to determine whether the association between plasma BNP concentration and cardiovascular mortality is sustained or diminishes with increasing time after BNP is measured. METHODS AND RESULTS: Six thousand seven hundred forty patients with a history of myocardial infarction or unstable angina who participated in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) trial had plasma BNP concentration measured at baseline and after 1 year. Associations with cardiovascular mortality were evaluated in landmark analyses 1 to <5,..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
The LIPID Study was originally funded by Bristol--Myers Squibb (Princeton, NJ) and conducted under the auspices of the National Heart Foundation of Australia (Melbourne, Australia). This biomarker research was also supported by project grant 490968 from the National Health and Medical Research Council of Australia. The design, management, analysis, and interpretation of this substudy were conducted independently of the study sponsor.